Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TTR | P02766 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931777 | 1.00 | SLC7A5 (0.52) | SLC7A5MEN1KMT2AADORA3HSD17B10 | |
| SCHEMBL2674679 | 1.00 | SLC7A5 (0.52) | SLC7A5MEN1KMT2AADORA3HSD17B10 | |
| SCHEMBL2674668 | 1.00 | SLC7A5 (0.52) | SLC7A5MEN1KMT2AADORA3HSD17B10 | |
| SCHEMBL28087654 | 0.90 | SLC7A5 (0.47) | SLC7A5MEN1KMT2AADORA3HSD17B10 | |
| SCHEMBL15085708 | 0.90 | SLC7A5 (0.47) | SLC7A5MEN1KMT2AADORA3HSD17B10 | |
| SCHEMBL5379357 | 0.88 | SLC7A5 (0.46) | SLC7A5MEN1KMT2AADORA3HSD17B10 | |
| SCHEMBL9162835 | 0.85 | ALDH1A1 (0.54) | MEN1KMT2APTGS2HTR2BALDH1A1 | |
| SCHEMBL9162838 | 0.85 | ALDH1A1 (0.54) | MEN1KMT2APTGS2HTR2BALDH1A1 | |
| SCHEMBL491220 | 0.84 | LDHA (0.67) | MEN1KMT2AHSD17B10PTGS2HTR2B | |
| SCHEMBL5302134 | 0.84 | SLC7A5 (0.55) | SLC7A5MEN1KMT2AADORA3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173128-B2 | Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody | IRM LLC (BM) | 2012-05-08 | — | — | US | disclosed |
| CN-1750843-B | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC | 2011-09-28 | — | — | CN | disclosed |
| EP-1576179-B1 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2010-09-15 | — | — | EP | disclosed |
| CN-100415770-C | 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}- alkylboronic acid derivatives | NOVARTIS AG (CH) | 2008-09-03 | — | — | CN | disclosed |
| US-7229617-B2 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC (BM) | 2007-06-12 | — | — | US | disclosed |
| US-20070128204-A1 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC (BM) | 2007-06-07 | — | — | US | disclosed |
| EP-1576179-A4 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2007-06-06 | — | — | EP | disclosed |
| CN-1750843-A | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC (BM) | 2006-03-22 | — | — | CN | disclosed |
| EP-1399468-B1 | 2-((N-(2-AMINO-3-(HETEROARYL OR ARYL)PROPIONYL)-AMINOACYL)-AMINO)-ALKYLBORONIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2006-02-15 | — | — | EP | disclosed |
| US-20050239716-A1 | 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives | FURET PASCAL | 2005-10-27 | — | — | US | disclosed |
| EP-1576179-A2 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2005-09-21 | — | — | EP | disclosed |
| US-6933290-B2 | 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives | NOVARTIS AG (CH) | 2005-08-23 | — | — | US | disclosed |
| US-20050079172-A1 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-04-14 | — | — | US | disclosed |
| US-20040167337-A1 | 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives | NOVARTIS AG (CH) | 2004-08-26 | — | — | US | disclosed |
| CN-1512999-A | 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}- alkylboronic acid derivatives | ��˹��ŵ�� | 2004-07-14 | — | — | CN | disclosed |
| WO-2004050895-A2 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2004-06-17 | — | — | WO | disclosed |
| EP-1399468-A1 | 2-((N-(2-AMINO-3-(HETEROARYL OR ARYL)PROPIONYL)-AMINOACYL)-AMINO)-ALKYLBORONIC ACID DERIVATIVES | Novartis AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002096933-A1 | 2-{[N-(2-AMINO-3-(HETEROARYL OR ARYL)PROPIONYL)-AMINOACYL]-AMINO}-ALKYLBORONIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167337-A1 | 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives | AADAT, BCAT1, BCAT2 | SLC7A5 46/4885MEN1 1127/4885KMT2A 1572/4885 |
| US-20050239716-A1 | 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives | AADAT, PIGS, SLC1A5 | SLC7A5 24/4885MEN1 1993/4885KMT2A 2555/4885 |
| US-20050079172-A1 | Methods and compositions for inducing apoptosis in cancer cells | BAD, BAX, CASP3 | SLC7A5 4840/4885MEN1 4510/4885KMT2A 4692/4885 |
| US-20070128204-A1 | Methods and compositions for inducing apoptosis in cancer cells | BAD, BAX, BID | SLC7A5 4845/4885MEN1 4481/4885KMT2A 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.